Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
EHC 2023
Programm
Suche
DE
Alle Personen
Cristina Tassorelli
Sortiert nach Typ
Datum
Invited speaker
Invited lecture
Clinical manifestation of aura
Vortrag
ePoster
P042
Efficacy of fremanezumab in reducing Monthly Migraine Days (MMD) and depression severity in patients from european countries with Migraine and Major Depressive Disorder (MDD)
Weitere Beteiligungen
Abstract lecture
AL006
Headwork as innovative tool for monitoring mAbs efficacy in migraine and their influence on work activity: a multicentric experience
ePoster
P019
Benefit-Risk assessment of atogepant vs. placebo in participants with episodic migraine who had prior inadequate response to 2–4 classes of oral preventive treatment: a post-hoc analysis of the ELEVATE trial
ePoster
P021
Predictors of ≥50% and ≥75% response to anti-CGRP monoclonal antibodies for migraine prevention in real life: results from a european multicenter observational study including 5818 patients
ePoster
P060
Effectiveness and tolerability of CGRP monoclonal antibodies in combination with monoclonal antibodies for other diseases: a multicenter study
ePoster
P022
Atogepant demonstrates early functional and quality of life improvements for the preventive treatment of episodic migraine after prior inadequate response to treatment: results from the ELEVATE trial
ePoster
P023
Effectiveness of galcanezumab versus traditional oral migraine preventive medications: 3-month findings from the TRIUMPH observational study
ePoster
P112
Design of the ContemporAry ProspecTive Understanding of migraine Real-world Evidence (CAPTURE) study
ePoster
P113
The burden of migraine: 3-month findings from the TRIUMPH (preventive
TR
eatment of m
I
graine: o
U
tco
M
es for
P
atients in Real-world
H
ealthcare Systems) study
ePoster
P042
Efficacy of fremanezumab in reducing Monthly Migraine Days (MMD) and depression severity in patients from european countries with Migraine and Major Depressive Disorder (MDD)
ePoster
P026
Effectiveness of galcanezumab vs. traditional oral migraine preventive medications: 3-month results from Real-World TRIUMPH study for Europe [Germany, Italy, Spain, and the United Kingdom]
ePoster
P045
Effect of atogepant on the migraine disability assessment, work productivity and activity impairment questionnaire, and patient global impression of change: results from the ELEVATE trial
ePoster
P050
The impact of fremanezumab treatment on depression severity in patients with concomitant antidepressant use: post hoc analysis of the UNITE study
ePoster
P017
Real-World effectiveness and safety of fremanezumab in migraine: 3rd interim analysis of the pan-european PEARL study
ePoster
P106
Network meta-analysis of atogepant vs. CGRP mAbs on migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine
ePoster
P053
How does chronic migraine change during three one-year cycles of CGRP-targeting monoclonal antibodies? A real-life study
Abstract lecture
AL010
Peripheral monocytes differentiation and cytokines inflammatory profile in episodic and chronic migraine: association with disease severity
ePoster
P234
The thalamic ventral posterior nuclear complex involvement in the migraine cycle: a task-free fMRI analysis during nitroglycerin-induced migraine like attacks
ePoster
P292
Effectiveness of transcranial direct current stimulation and monoclonal antibodies acting on the CGRP as a combined treatment for migraine (TACTIC) – preliminary results
ePoster
P211
Psychological profiles and clinical characteristics of migraine patients with early life traumas
ePoster
P270
Role of the resting state networks in episodic cluster headache: cerebral connectivity analysis with Hd-Eeg
ePoster
P214
Brain connectivity changes induced by monoclonal antibodies targeting the CGRP pathway in migraine patients: a prospective HD-EEG Study
ePoster
P216
Expression of miR-155 in migraine: association with migraine phenotypes and disease severity
ePoster
P217
Hypothalamus involvement in the migraine cycle: a task-free fMRI analysis during nitroglycerin-induced attacks
Abstract lecture
AL014
Psychological profiles of super responders and non-responders to CGRP-monoclonal antibodies: data from a 6-month follow-up
v1.21.0
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz